vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Atmus Filtration Technologies Inc. (ATMU). Click either name above to swap in a different company.
Atmus Filtration Technologies Inc. is the larger business by last-quarter revenue ($446.6M vs $247.1M, roughly 1.8× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 10.7%, a 0.4% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 9.8%). Atmus Filtration Technologies Inc. produced more free cash flow last quarter ($31.2M vs $29.1M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 2.3%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Atmus Filtration Technologies Inc. designs, manufactures and distributes high-performance filtration products and tailored solutions. Its portfolio covers air, fuel, oil and hydraulic filtration systems, serving global automotive, heavy-duty vehicle, industrial equipment and aerospace end markets, for both original equipment manufacturers and aftermarket replacement customers.
ANIP vs ATMU — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $446.6M |
| Net Profit | $27.5M | $48.0M |
| Gross Margin | — | 28.5% |
| Operating Margin | 14.1% | 15.8% |
| Net Margin | 11.1% | 10.7% |
| Revenue YoY | 29.6% | 9.8% |
| Net Profit YoY | 367.5% | 19.7% |
| EPS (diluted) | $1.14 | $0.58 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $446.6M | ||
| Q3 25 | $227.8M | $447.7M | ||
| Q2 25 | $211.4M | $453.5M | ||
| Q1 25 | $197.1M | $416.5M | ||
| Q4 24 | $190.6M | $406.7M | ||
| Q3 24 | $148.3M | $403.7M | ||
| Q2 24 | $138.0M | $432.6M | ||
| Q1 24 | $137.4M | $426.6M |
| Q4 25 | $27.5M | $48.0M | ||
| Q3 25 | $26.6M | $54.8M | ||
| Q2 25 | $8.5M | $59.9M | ||
| Q1 25 | $15.7M | $44.7M | ||
| Q4 24 | $-10.3M | $40.1M | ||
| Q3 24 | $-24.2M | $43.8M | ||
| Q2 24 | $-2.3M | $56.2M | ||
| Q1 24 | $18.2M | $45.5M |
| Q4 25 | — | 28.5% | ||
| Q3 25 | — | 28.9% | ||
| Q2 25 | — | 28.9% | ||
| Q1 25 | — | 26.5% | ||
| Q4 24 | — | 26.3% | ||
| Q3 24 | — | 27.6% | ||
| Q2 24 | — | 30.5% | ||
| Q1 24 | — | 26.2% |
| Q4 25 | 14.1% | 15.8% | ||
| Q3 25 | 15.9% | 18.3% | ||
| Q2 25 | 6.6% | 18.0% | ||
| Q1 25 | 13.3% | 15.6% | ||
| Q4 24 | -2.3% | 13.4% | ||
| Q3 24 | -13.8% | 15.7% | ||
| Q2 24 | 3.7% | 18.4% | ||
| Q1 24 | 14.8% | 16.1% |
| Q4 25 | 11.1% | 10.7% | ||
| Q3 25 | 11.7% | 12.2% | ||
| Q2 25 | 4.0% | 13.2% | ||
| Q1 25 | 8.0% | 10.7% | ||
| Q4 24 | -5.4% | 9.9% | ||
| Q3 24 | -16.3% | 10.8% | ||
| Q2 24 | -1.7% | 13.0% | ||
| Q1 24 | 13.2% | 10.7% |
| Q4 25 | $1.14 | $0.58 | ||
| Q3 25 | $1.13 | $0.66 | ||
| Q2 25 | $0.36 | $0.72 | ||
| Q1 25 | $0.69 | $0.54 | ||
| Q4 24 | $-0.45 | $0.49 | ||
| Q3 24 | $-1.27 | $0.52 | ||
| Q2 24 | $-0.14 | $0.67 | ||
| Q1 24 | $0.82 | $0.54 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $236.4M |
| Total DebtLower is stronger | — | $570.0M |
| Stockholders' EquityBook value | $540.7M | $378.5M |
| Total Assets | $1.4B | $1.4B |
| Debt / EquityLower = less leverage | — | 1.51× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $236.4M | ||
| Q3 25 | $262.6M | $218.3M | ||
| Q2 25 | $217.8M | $190.8M | ||
| Q1 25 | $149.8M | $183.3M | ||
| Q4 24 | $144.9M | $184.3M | ||
| Q3 24 | $145.0M | $196.8M | ||
| Q2 24 | $240.1M | $160.5M | ||
| Q1 24 | $228.6M | $149.2M |
| Q4 25 | — | $570.0M | ||
| Q3 25 | — | $577.5M | ||
| Q2 25 | — | $585.0M | ||
| Q1 25 | — | $588.8M | ||
| Q4 24 | — | $592.5M | ||
| Q3 24 | — | $596.2M | ||
| Q2 24 | — | $600.0M | ||
| Q1 24 | — | $600.0M |
| Q4 25 | $540.7M | $378.5M | ||
| Q3 25 | $505.8M | $336.7M | ||
| Q2 25 | $436.8M | $316.3M | ||
| Q1 25 | $418.6M | $265.3M | ||
| Q4 24 | $403.7M | $227.4M | ||
| Q3 24 | $405.9M | $221.2M | ||
| Q2 24 | $455.8M | $178.1M | ||
| Q1 24 | $452.0M | $121.8M |
| Q4 25 | $1.4B | $1.4B | ||
| Q3 25 | $1.4B | $1.3B | ||
| Q2 25 | $1.3B | $1.3B | ||
| Q1 25 | $1.3B | $1.2B | ||
| Q4 24 | $1.3B | $1.2B | ||
| Q3 24 | $1.3B | $1.2B | ||
| Q2 24 | $920.8M | $1.2B | ||
| Q1 24 | $914.5M | $1.1B |
| Q4 25 | — | 1.51× | ||
| Q3 25 | — | 1.72× | ||
| Q2 25 | — | 1.85× | ||
| Q1 25 | — | 2.22× | ||
| Q4 24 | — | 2.61× | ||
| Q3 24 | — | 2.70× | ||
| Q2 24 | — | 3.37× | ||
| Q1 24 | — | 4.93× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $47.5M |
| Free Cash FlowOCF − Capex | $29.1M | $31.2M |
| FCF MarginFCF / Revenue | 11.8% | 7.0% |
| Capex IntensityCapex / Revenue | 0.5% | 3.6% |
| Cash ConversionOCF / Net Profit | 1.10× | 0.99× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $148.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $47.5M | ||
| Q3 25 | $44.1M | $82.1M | ||
| Q2 25 | $75.8M | $44.4M | ||
| Q1 25 | $35.0M | $28.7M | ||
| Q4 24 | $15.9M | $20.0M | ||
| Q3 24 | $12.5M | $70.7M | ||
| Q2 24 | $17.4M | $22.9M | ||
| Q1 24 | $18.3M | $-8.2M |
| Q4 25 | $29.1M | $31.2M | ||
| Q3 25 | $38.0M | $68.9M | ||
| Q2 25 | $71.8M | $32.4M | ||
| Q1 25 | $32.5M | $16.3M | ||
| Q4 24 | $13.5M | $10.0M | ||
| Q3 24 | $7.7M | $54.3M | ||
| Q2 24 | $13.0M | $11.3M | ||
| Q1 24 | $13.7M | $-18.8M |
| Q4 25 | 11.8% | 7.0% | ||
| Q3 25 | 16.7% | 15.4% | ||
| Q2 25 | 34.0% | 7.1% | ||
| Q1 25 | 16.5% | 3.9% | ||
| Q4 24 | 7.1% | 2.5% | ||
| Q3 24 | 5.2% | 13.5% | ||
| Q2 24 | 9.4% | 2.6% | ||
| Q1 24 | 10.0% | -4.4% |
| Q4 25 | 0.5% | 3.6% | ||
| Q3 25 | 2.7% | 2.9% | ||
| Q2 25 | 1.9% | 2.6% | ||
| Q1 25 | 1.3% | 3.0% | ||
| Q4 24 | 1.3% | 2.5% | ||
| Q3 24 | 3.2% | 4.1% | ||
| Q2 24 | 3.2% | 2.7% | ||
| Q1 24 | 3.3% | 2.5% |
| Q4 25 | 1.10× | 0.99× | ||
| Q3 25 | 1.66× | 1.50× | ||
| Q2 25 | 8.87× | 0.74× | ||
| Q1 25 | 2.23× | 0.64× | ||
| Q4 24 | — | 0.50× | ||
| Q3 24 | — | 1.61× | ||
| Q2 24 | — | 0.41× | ||
| Q1 24 | 1.00× | -0.18× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
ATMU
| Fuel Products | $219.1M | 49% |
| Lube | $84.8M | 19% |
| Air | $74.0M | 17% |
| Other | $68.7M | 15% |
| Related Party | $14.9M | 3% |
